

U.S. National Library of Medicine National Center for Biotechnology Information **NLM Citation:** Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Elotuzumab. [Updated 2018 Dec 3]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Elotuzumab

Revised: December 3, 2018.

CASRN: 915296-00-3

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of elotuzumab during breastfeeding. Because elotuzumab is a large protein molecule with a molecular weight of 148,100, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. However, elotuzumab is administered with dexamethasone and lenalidomide, two drugs which also have no information on use in nursing mothers. The manufacturer recommends that women receiving elotuzumab should not breastfeed.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Elotuzumab

CAS Registry Number

915296-00-3

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site .

Drug Class

Breast Feeding

Lactation

Antibodies, Monoclonal, Humanized

Antineoplastic Agents